Crispr Therapeutics Stock News

CRISPR Therapeutics AG (NASDAQ:CRSP) has a beta value of 2.07 and has seen 1.35 million shares traded in the last trading session. The company, currently valued at $5.65B, closed the last trade at $79.92 per share which meant it lost -$1.13 on the day or -1.39% during that session. The CRSP stock price is -175.53% CRISPR Therapeutics AG (CRSP): What Makes The Stock Good? Read More »

CRISPR Therapeutics (NASDAQ:CRSP) and Clarus Therapeutics (NASDAQ:CRXT) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, profitability, institutional ownership, analyst recommendations, valuation, dividends and risk. Institutional & Insider Ownership 51.8% of CRISPR Therapeutics shares are owned by institutional investors. Comparatively, 79.7% []

Vertex: Waiting For The Pipeline Success

If you're looking for bargain stocks to buy that are down 30% or more in 2021, that's not an easy task. Here are 10 that fit the bill.

Atlas Capital Advisors LLC lessened its position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 50.0% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,600 shares of the companys stock after selling 1,600 shares during the period. Atlas Capital []

CRISPR Therapeutics is a gene therapy company pioneering the CRISPR/Cas9 gene editing tool, discovered by its scientific co-founder. The company is partnered with Vertex - a $58bn market cap biotech w

Brokerages expect CRISPR Therapeutics AG (NASDAQ:CRSP) to post $5.39 million in sales for the current quarter, according to Zacks. Six analysts have provided estimates for CRISPR Therapeutics earnings, with estimates ranging from $500,000.00 to $16.50 million. CRISPR Therapeutics reported sales of $370,000.00 in the same quarter last year, which indicates a positive year over year []

ARK Genomic ETF: Likely Economic Victim With Low Institutional Interest

Investors need to pay close attention to CRISPR Therapeutics (CRSP) stock based on the movements in the options market lately.

"Industry analysis is a crucial step in the current competitive market space that helps identify the right target customers and accordingly provide tailored solutions for their business needs. Every aspect and unique challenges put up by the particular industry are

The stock price of CRISPR Therapeutics, a biotechnology gene editing company focused on developing gene-based medicines for human diseases, reached an all-time high of $210 in January of this year bef

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Don''t let the downtrend in CRSP stock fool you; the company is still making headway in advancing potentially life-changing therapeutics. The post CRISPR Therapeutics Is One of Todays Best Biotech Value Investments appeared first on InvestorPlace . More From InvestorPlace Stock Prodigy Who Found NIO at $2 Says Buy THIS Now Man Who Called Black Monday: Prepare Now. #1 EV Stock Still Flying Under the Radar Interested in Crypto? Read This First

Don't let the downtrend in CRSP stock fool you; the company is still making headway in advancing potentially life-changing therapeutics. The post CRISPR Therapeutics Is One of Today's Best Biotech Val